Pfizer is a leader in corporate governance, and good corporate governance is fundamental to Pfizer's business. A cornerstone of governance at Pfizer is our shareholder outreach program, through which we regularly engage with our investors and stakeholders around the world to gain insight into the burgeoning issues at the forefront of their business policies and guidelines. We aim to seek a more collaborative approach to specific issues of importance to us and our industry. Shareholder input helps us to continue to drive innovations in policies and disclosures on corporate political activities and other key governance areas.
Our annually elected board of directors is comprised entirely of independent directors (with the only exception being our CEO, Ian Read). Each Director provides a unique business perspective, experience and skills, all valuable to the Company. The board plays a vital oversight role, which fosters shareholder value and affects stakeholder confidence, through discussions with senior leaders and external advisers covering a wide range of matters including strategy, financial performance, compliance, and public policy.
Regulatory reforms have resulted in the transformation of the corporate governance landscape and Pfizer has embraced these amendments, and in some cases has been ahead of the game in adopting innovations that are now requirements. It is essential that we practice responsible business principles, and continue to demonstrate our commitment to excellence to sustain value for our investors and stakeholders.
The Pfizer Board understands and acts on the fundamental principle that good corporate governance is critical to organizational success and the protection of shareholder value. In 1994, the Pfizer Board took the unprecedented step of creating a corporate governance committee of the Board. The first act of the Committee was to issue a new set of principles to govern the operation of the Board and its Committees.
In keeping with the Board's forward thinking and accountability to shareholders, these Principles were published in Pfizer's proxy statement well before NYSE mandated guidelines in 2003. The Principles are a living document, reviewed at least annually, and updated periodically in response to changing regulatory requirements, evolving best practices, and concerns of our shareholder and all stakeholders.
Download Corporate Governance Principles
Pfizer's Board Committees are integral in defining the corporate structure and governance principles. Download the Corporate Governance Principles and meet the current committees.
Board Committees & Charters Board Policies. Pfizer's Board of Directors implement policies to ensure ethical conduct for members of the leadership team. For inquiries, contact our Board of Directors.
Learn more about Pfizer's approach to corporate governance, compliance, responsibility, and more.
For more information on Pfizer policies, products and more, contact any of Pfizer's directors via e-mail.
The webcast may include forward-looking statements about, among other things, our anticipated future operating and financial performance, business plans and prospects, in-line products and product candidates, strategic reviews, capital allocation, business-development plans, the benefits expected from our business development transactions and plans relating to share repurchases and dividends that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.
A description of these risks and uncertainties can be found in Pfizer’s most recent Annual Report on Form 10-K and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.
The forward-looking statements in the webcast speak only as of the original date of the webcast. Pfizer assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments.